Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Intradermal or sublingual delivery and heat-labile enterotoxin (LT) proteins shape immunologic outcomes to CFA/I fimbriae-derived subunit antigen vaccine against enterotoxigenic E. coli.

Maciel M Jr, Bauer D, Baudier RL, Bitoun J, Clements JD, Poole ST, Smith MA, Kaminski RW, Savarino SJ, Norton EB.

Infect Immun. 2019 Aug 19. pii: IAI.00460-19. doi: 10.1128/IAI.00460-19. [Epub ahead of print]

PMID:
31427449
2.

A High-throughput Shigella-specific Bactericidal Assay.

Weerts HP, Yu J, Kaminski RW, Nahm MH.

J Vis Exp. 2019 Feb 27;(144). doi: 10.3791/59164.

PMID:
30882773
3.

A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.

Frenck RW Jr, Baqar S, Alexander W, Dickey M, McNeal M, El-Khorazaty J, Baughman H, Hoeper A, Barnoy S, Suvarnapunya AE, Kaminski RW, Venkatesan MM.

Vaccine. 2018 Aug 6;36(32 Pt B):4880-4889. doi: 10.1016/j.vaccine.2018.06.063. Epub 2018 Jul 2.

PMID:
30037478
4.

Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay.

Nahm MH, Yu J, Weerts HP, Wenzel H, Tamilselvi CS, Chandrasekaran L, Pasetti MF, Mani S, Kaminski RW.

mSphere. 2018 Jun 13;3(3). pii: e00146-18. doi: 10.1128/mSphere.00146-18. Print 2018 Jun 27.

5.

Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.

Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW.

mSphere. 2018 Mar 28;3(2). pii: e00583-17. doi: 10.1128/mSphere.00583-17. eCollection 2018 Mar-Apr.

6.

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Porter CK, Lynen A, Riddle MS, Talaat K, Sack D, GutiƩrrez RL, McKenzie R, DeNearing B, Feijoo B, Kaminski RW, Taylor DN, Kirkpatrick BD, Bourgeois AL.

PLoS One. 2018 Mar 28;13(3):e0194325. doi: 10.1371/journal.pone.0194325. eCollection 2018.

7.

Improving chances for successful clinical outcomes with better preclinical models.

Wenzel H, Kaminski RW, Clarkson KA, Maciel M Jr, Smith MA, Zhang W, Oaks EV.

Vaccine. 2017 Dec 14;35(49 Pt A):6798-6802. doi: 10.1016/j.vaccine.2017.08.030. Epub 2017 Sep 7.

8.

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.

Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.

Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917. Print 2016 Dec.

9.

Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.

Lin J, Smith MA, Benjamin WH Jr, Kaminski RW, Wenzel H, Nahm MH.

Clin Vaccine Immunol. 2016 Aug 5;23(8):681-8. doi: 10.1128/CVI.00148-16. Print 2016 Aug.

10.

Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.

Gregory M, Kaminski RW, Lugo-Roman LA, Galvez Carrillo H, Tilley DH, Baldeviano C, Simons MP, Reynolds ND, Ranallo RT, Suvarnapunya AE, Venkatesan MM, Oaks EV.

Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4.

11.

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.

12.

Multiplexed immunoassay to assess Shigella-specific antibody responses.

Kaminski RW, Clarkson K, Kordis AA, Oaks EV.

J Immunol Methods. 2013 Jul 31;393(1-2):18-29. doi: 10.1016/j.jim.2013.04.002. Epub 2013 Apr 9.

PMID:
23583496
13.

Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.

Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, Venkatesan MM.

Vaccine. 2012 Jul 20;30(34):5159-71. doi: 10.1016/j.vaccine.2012.05.003. Epub 2012 May 30.

PMID:
22658966
14.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.

PMID:
21787825
15.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
16.

Inactivated and subunit vaccines to prevent shigellosis.

Kaminski RW, Oaks EV.

Expert Rev Vaccines. 2009 Dec;8(12):1693-704. doi: 10.1586/erv.09.127. Review.

PMID:
19943764
17.

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Ranallo RT, Kaminski RW, George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM.

Infect Immun. 2010 Jan;78(1):400-12. doi: 10.1128/IAI.00533-09. Epub 2009 Nov 2.

18.

Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV.

Clin Vaccine Immunol. 2009 Apr;16(4):574-86. doi: 10.1128/CVI.00435-08. Epub 2009 Feb 18.

19.

Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

Turbyfill KR, Kaminski RW, Oaks EV.

Vaccine. 2008 Mar 4;26(10):1353-64. doi: 10.1016/j.vaccine.2007.12.040. Epub 2008 Jan 17.

PMID:
18276045
20.

IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri.

Espina M, Olive AJ, Kenjale R, Moore DS, Ausar SF, Kaminski RW, Oaks EV, Middaugh CR, Picking WD, Picking WL.

Infect Immun. 2006 Aug;74(8):4391-400.

21.

Mucosal adjuvant properties of the Shigella invasin complex.

Kaminski RW, Turbyfill KR, Oaks EV.

Infect Immun. 2006 May;74(5):2856-66.

22.

Collection and processing of mucosal secretions from mice.

Kaminski RW, Vancott TC.

Methods Mol Med. 1999;17:329-39. doi: 10.1385/0-89603-369-4:329.

PMID:
21380685
23.

HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.

VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL.

J Immunol. 1998 Feb 15;160(4):2000-12.

24.

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

VanCott TC, Mascola JR, Kaminski RW, Kalyanaraman V, Hallberg PL, Burnett PR, Ulrich JT, Rechtman DJ, Birx DL.

J Virol. 1997 Jun;71(6):4319-30.

25.

Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG.

Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis-Price L, Smith G, Redfield RR, Amselem S, Birx DL.

J Infect Dis. 1997 Feb;175(2):292-301.

PMID:
9203649
26.

Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Lowell GH, Colleton C, Frost D, Kaminski RW, Hughes M, Hatch J, Hooper C, Estep J, Pitt L, Topper M, Hunt RE, Baker W, Baze WB.

Infect Immun. 1996 Nov;64(11):4686-93.

27.
28.

Supplemental Content

Loading ...
Support Center